Browse Studies — Arctuva

Phase 3

Comparing Treatment With Versus Without Neoadjuvant Doxorubicin and Ifosfamide in Selected Patients With High-Risk Resectable Soft-Tissue Sarcoma

This phase III trial compares the effect of adding doxorubicin and ifosfamide (AIM chemotherapy) before (neoadjuvant) receiving standard treatment with pembrol…

Resectable LiposarcomaResectable Soft Tissue SarcomaResectable Undifferentiated Pleomorphic Sarcoma

Estimated

~$50 – $1,500

Actual pay is set by the research site.

Ohio State University Comprehensive Cancer CenterNCT07823491

Phase 1

A First-in-human, Phase 1/2, Multicenter, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of ADCE-D01, a Humanized Anti-human uPARAP Antibody Linked to a Topoisomerase I Inhibitor, in Patients With Metastatic and/or Unresectable Soft Tissue Sarcoma

The goal of this clinical trial is to learn about the safety, tolerability and efficacy of ADCE-D01.

Metastatic Soft Tissue SarcomaUnresectable Soft Tissue Sarcoma

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Adcendo ApSNCT06797999

Phase 3

Phase III Randomized Study Testing Non-Inferiority of Short-Course Ultra-Hypofractionated Radiation (UHRT-5) Versus Standard Fractionation (RT-25) for Stage II-IIIB, Extremity, Resectable Soft Tissue Sarcoma

This clinical trial compares the effect of short-course ultrahypofractionated radiation therapy over 5 days (UHRT-5) to standard-course radiation therapy over …

Recurrent Soft Tissue Sarcoma of the Trunk and ExtremitiesResectable Soft Tissue Sarcoma of the Trunk and ExtremitiesSoft Tissue Sarcoma of the Trunk and Extremities+2 more

Estimated

~$50 – $2,250

Actual pay is set by the research site.